IL225312A0 - New combinations - Google Patents

New combinations

Info

Publication number
IL225312A0
IL225312A0 IL225312A IL22531213A IL225312A0 IL 225312 A0 IL225312 A0 IL 225312A0 IL 225312 A IL225312 A IL 225312A IL 22531213 A IL22531213 A IL 22531213A IL 225312 A0 IL225312 A0 IL 225312A0
Authority
IL
Israel
Prior art keywords
novel combinations
novel
combinations
Prior art date
Application number
IL225312A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astrazeneca Ab
Ivanova Svetlana
Burkamp Frank
Hansen Peter Robert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Ivanova Svetlana, Burkamp Frank, Hansen Peter Robert filed Critical Astrazeneca Ab
Publication of IL225312A0 publication Critical patent/IL225312A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL225312A 2010-10-07 2013-03-18 New combinations IL225312A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1016912.6A GB201016912D0 (en) 2010-10-07 2010-10-07 Novel combination
PCT/GB2011/051898 WO2012046050A1 (en) 2010-10-07 2011-10-05 Novel combinations

Publications (1)

Publication Number Publication Date
IL225312A0 true IL225312A0 (en) 2013-06-27

Family

ID=43304217

Family Applications (1)

Application Number Title Priority Date Filing Date
IL225312A IL225312A0 (en) 2010-10-07 2013-03-18 New combinations

Country Status (14)

Country Link
EP (1) EP2624838A1 (ru)
JP (1) JP2013538867A (ru)
KR (1) KR20130126595A (ru)
CN (1) CN103249418A (ru)
AU (1) AU2011311310A1 (ru)
BR (1) BR112013008362A2 (ru)
CA (1) CA2813684A1 (ru)
GB (1) GB201016912D0 (ru)
IL (1) IL225312A0 (ru)
IN (1) IN2013MN00567A (ru)
MX (1) MX2013003816A (ru)
RU (1) RU2013115103A (ru)
SG (1) SG188575A1 (ru)
WO (1) WO2012046050A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150027922A (ko) * 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
KR101657678B1 (ko) * 2013-11-05 2016-09-20 주식회사 대웅제약 신규한 화합물, 이의 제조방법 및 이를 포함하는 항진균제 조성물
AR106697A1 (es) * 2015-11-16 2018-02-07 Esteve Labor Dr Compuestos oxadiazoespíricos para el tratamiento del abuso y la adicción a las drogas
CN109195975B (zh) * 2016-09-30 2022-01-04 四川海思科制药有限公司 一种二氮杂螺[5.5]十一碳烷衍生物及其用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60224172T2 (de) 2001-03-22 2008-12-04 Glaxo Group Ltd., Greenford Formanilid-derivative als beta2-adrenorezeptor-agonisten
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
DK1425001T3 (da) 2001-09-14 2009-04-14 Glaxo Group Ltd Phenethanolaminderivater til behandling af respiratoriske sygdomme
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
CA2499314C (en) 2002-10-11 2010-08-24 Pfizer Inc. Indole derivatives as beta-2 agonists
AR041724A1 (es) 2002-10-28 2005-05-26 Glaxo Group Ltd Compuestos derivados de fenetanolamina y su utilizacion en composiciones farmaceuticas
SE0300091D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
JP4616264B2 (ja) 2003-05-28 2011-01-19 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
CA2543858C (en) 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7402673B2 (en) 2004-06-03 2008-07-22 Theravance, Inc. Diamine β2 adrenergic receptor agonists
US20060002967A1 (en) 2004-07-01 2006-01-05 Smestad Thomas L Resorbable implant with lubricious coating
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7528253B2 (en) 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0425057D0 (en) 2004-11-12 2004-12-15 Pfizer Ltd L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
US20060114254A1 (en) 2004-11-26 2006-06-01 Tim Day Volume rendering apparatus and method
WO2006066907A1 (en) 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
GB0512246D0 (en) 2005-06-15 2005-07-27 Glaxo Group Ltd Novel pharmaceutical
MX2008011963A (es) 2006-03-20 2008-10-01 Pfizer Ltd Derivados de amina.
ES2296516B1 (es) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
CA2660186A1 (en) 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of respiratory diseases
PE20081358A1 (es) 2006-08-22 2008-10-31 Boehringer Ingelheim Int Combinaciones farmacologicas para el tratamiento de enfermedades de la vias aereas
CA2665385A1 (en) 2006-10-04 2008-04-10 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
ES2302447B1 (es) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
SA08280783B1 (ar) 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
WO2008106016A2 (en) 2007-02-27 2008-09-04 Metrosol, Inc. Prism spectrometer with moveable detector element and with collimated input light
GB0703999D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
DK2170848T3 (en) 2007-06-27 2015-01-05 Astrazeneca Ab Pyrazinonderivater and their use to treat lung diseases
KR20100087147A (ko) * 2007-10-04 2010-08-03 아스트라제네카 아베 글루코코르티코이드 활성을 갖는 스테로이드성 [3,2-ｃ]피라졸 화합물
NZ586872A (en) 2008-02-06 2012-03-30 Astrazeneca Ab Spirocyclic amide compounds
AU2009247021B2 (en) 2008-05-13 2012-06-07 Astrazeneca Ab Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
EP2300464A1 (en) 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
UY32520A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802

Also Published As

Publication number Publication date
IN2013MN00567A (ru) 2015-10-09
EP2624838A1 (en) 2013-08-14
WO2012046050A1 (en) 2012-04-12
SG188575A1 (en) 2013-04-30
CN103249418A (zh) 2013-08-14
CA2813684A1 (en) 2012-04-12
GB201016912D0 (en) 2010-11-24
KR20130126595A (ko) 2013-11-20
JP2013538867A (ja) 2013-10-17
BR112013008362A2 (pt) 2016-06-14
MX2013003816A (es) 2013-05-01
RU2013115103A (ru) 2014-11-20
AU2011311310A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
DK3342786T3 (en) Anti-dll3-antistof
AP3107A (en) 5-Alkynyl-pyrimidines
EP2566479A4 (en) AZA-INDAZOLES
EP2640189A4 (en) 3-deutero-pomalidomide
EP2534256A4 (en) NEW USES
DK3466977T3 (en) Anti-vla-4-antistoffer
EP2651505A4 (en) ELECTROPORATION-INDUCED ELECTROSENSIBILIZATION
EP2641891A4 (en) PKC ACTIVATOR-
GB201013207D0 (en) Novel combination
GB201001760D0 (en) Dipenser
IL225312A0 (en) New combinations
GB201000196D0 (en) Novel combination
GB201001546D0 (en) Knocktop
GB201001385D0 (en) Cable-tidies
AU4536P (en) TB01 Tibouchina urvilleana
AU4937P (en) FlatinsulGL Myoporum insulare
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
GB201019442D0 (en) Novel combinations
GB201002829D0 (en) Novel copmounds
GB201013212D0 (en) Novel combination
GB201013209D0 (en) Novel combination
GB201013211D0 (en) Novel combination
GB201013214D0 (en) Novel combination